Why Korio Took A Platform-First Approach To Clinical Trial RTSM

The clinical trial landscape has long been burdened by "bespoke" IRT systems—one-off builds that require specialized engineering to maintain. This paradigm often leads to fragmented workflows and a steep learning curve for every new study. Moving away from this manual, repetitive cycle requires a fundamental shift in how randomization and trial supply management (RTSM) software is architected.

By prioritizing a platform-first approach, the focus shifts from rebuilding core logic to leveraging reusable components and standardized behaviors. For sponsors and CROs, the primary benefit is a significant reduction in technical debt and operational variability. Embracing a system designed for scalability allows clinical teams to establish controlled standards at the client level. Understanding why this infrastructure matters is essential for any clinical professional aiming to move beyond the limitations of "one-off" delivery and toward a more sustainable, long-term digital strategy.